| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| Myeloma - Plasma Cell Malignancy Alternative Names: Multiple myeloma, plasma cell myeloma Type: Hematologic malignancy / plasma cell cancer Origin: Malignant transformation and clonal expansion of antibody-producing plasma cells, usually within the bone marrow. Function/Characteristics: Myeloma cells produce monoclonal immunoglobulins or light chains and can disrupt normal bone marrow function, bone remodeling, renal function, and immune regulation. Common Features: Bone marrow infiltration, osteolytic bone lesions, anemia, elevated monoclonal protein, renal dysfunction, hypercalcemia, and impaired normal antibody production. Common Markers: CD38, CD138, BCMA (TNFRSF17), SLAMF7, and monoclonal immunoglobulin/light-chain expression. |
| 7437- | CYN, | Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma |
| - | in-vitro, | Mye, | AMO1 | - | in-vivo, | Mye, | NA | - | in-vitro, | Mye, | KMS11 | - | in-vitro, | Mye, | JJN3 | - | in-vitro, | Mye, | MolP8 | - | in-vitro, | Mye, | L363 | - | in-vitro, | Mye, | H929 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:92 Cells:% prod#:% Target#:323 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid